OthersFriday, October 04, 2013, 15:30 - 17:00
Smoking and risk of treatment-induced neutralizing antibodies to interferon beta 1aA.K. Hedström, M. Ryner, K. Fink, A. Fogdell-Hahn, L. Alfredsson, T. Olsson, J. Hillert (Stockholm, SE)
Background: Neutralizing antibodies (NAbs) to interferon beta (IFNbeta) products that develop during treatment are associated with a loss of clinical efficacy. The aim of this study was to investigate the influence of smoking habits on the risk of developing NAbs to IFNbeta in the treatment of multiple sclerosis (MS).
Methods: This report is based on 699 IFNbeta-1a treated MS patients included in either of two Swedish case-control studies in which information on smoking habits was collected. Using logistic regression, the development of NAbs to IFNbeta-1a among current smokers was compared with that of non-smokers by calculating the odds ratio with a 95% confidence interval.
Results: Current smokers showed an increased risk of developing NAbs to IFNbeta-1a compared with non-smokers (odds ratio 1.8, 95% confidence interval 1.2-2.7, p=0.003). Among current smokers, we found clear evidence of a dose-response correlation between cumulative dose of smoking and the risk of developing NAbs to interferon beta-1a. There were no gender differences.
Conclusions: The finding that current smokers have an increased risk of developing NAbs to IFNbeta-1a has implications both for the practical care and the treatment of MS, and also provides interesting perspectives of the lungs as immune-reactive organs upon irritation.
Dr. Hedström reports no disclosures. Ryner has received research support from Biogen Idec, Sanofi Aventis and the Swedish Association for Persons with Neurological Disabilities, as well as payment for lectures from Biogen Idec. Dr. Fink Fink has received travel compensation for consulting work from Novartis and Teva. Dr. Fogdell-Hahn has received research grants from Association for Persons with Neurological Disabilities and IMI. She received unrestricted research grants from Merck-Serono, BiogenIdec; served as consultant for Jonson&Jonson; received honoraria for lectures by BiogenIdec and Sanofi-Aventis. Dr. Alfredsson receives research support from the Swedish Medical Research Council and Swedish Council for Working life and Social Research. Dr. Olsson served on scientific advisory boards for Merck-Serono, Biogen Idec, and SanofiAventis; served as Co-editor of Current Opinion in Immunology; received speaker honoraria from Novartis and Biogen Idec; and receives research support from Bayer Schering, Sanofi-Aventis, Biogen Idec, the Swedish Research Council, EU fp6 Neuropromise, EURATools, the Söderberg Foundation, Bibbi and Nils Jensens Foundation, the Montel Williams Foundation, and the Swedish Brain Foundation.
Dr. Hillert received honoraria for serving on advisory boards for BiogenIdec, Merck-Serono and Novartis and for speaker’s fees from BiogenIdec, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as P.I. for and received projects supported by BiogenIdec, Merck-Serono, and Bayer-Schering. His MS research is funded by the Swedish Research Council, Bibbi and Nils Jensens Foundation and the European Commission.
The work was supported by grants from the Swedish Medical Research Council; from the Swedish Council for Working Life and Social Research, the fp6 EU program Neuropromise, Bibbi and Niels Jensens foundation, Knut and Alice Wallenbergs Foundation, the Söderberg foundation, and the Swedish Association for Persons with Neurological Disabilities.